Markets:

Overview

News

Currencies

International

Treasuries

Insmed Incorporated - Common Stock (NQ:INSM)

102.15 +3.54 (+3.59%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jun 23, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Insmed Incorporated - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Tuesday's after hours session: top gainers and losers ↗

June 23, 2026

Via Chartmill

NWI Management Dumps 42,700 MercadoLibre Shares Worth $82.4 Million ↗

May 30, 2026

MercadoLibre delivers e-commerce and fintech solutions across Latin America, leveraging an integrated digital ecosystem for regional growth.

Via The Motley Fool

Topics Regulatory Compliance

Why This Fund Made a $189 Million Bet on Erasca as Shares Skyrocket 800% ↗

May 29, 2026

This clinical-stage biotech develops targeted oral therapies for RAS/MAPK-driven cancers, with all assets currently in development.

Via The Motley Fool

Topics Regulatory Compliance

Insmed (NASDAQ:INSM) Q1 Revenue Miss Triggers Pre-Market Slide Despite Narrower Loss ↗

May 07, 2026

Via Chartmill

Tango Therapeutics Stock Is Up 840%, and This Fund Just Disclosed Buying $164 Million More ↗

May 29, 2026

This biotechnology firm advances targeted cancer therapies, leveraging genetic insights and strategic partnerships in oncology.

Via The Motley Fool

Investment Firm Closes Out Entire $18.1 Million Position in Biotech Stock, According to Latest SEC Filing ↗

May 26, 2026

This biotech focuses on biologic therapies for immunological diseases, with lead candidates in nephrology and infectious disease.

Via The Motley Fool

Topics Regulatory Compliance

Insmed CEO Defends BRINSUPRI Launch as Sales Surge, TPIP Pipeline Gains Focus ↗

May 18, 2026

Insmed (NASDAQ:INSM) Chair and CEO Will Lewis said the company remains confident in the launch trajectory of BRINSUPRI, despite investor concerns over discontinuation rates that followed the company’s...

Via MarketBeat

Patient Square Makes a Big Bet on Nektar Pharmaceuticals (NKTR) Purchasing 210,000 Shares ↗

May 16, 2026

This biotech firm develops immunotherapies for cancer and autoimmune diseases, with several candidates advancing through clinical trials.

Via The Motley Fool

This Nuclear Tech Stock Grew Revenue 27%, But a Fund Still Slashed Its Stake ↗

May 15, 2026

Mirion Technologies delivers radiation detection and monitoring solutions to healthcare and industrial clients worldwide.

Via The Motley Fool

Topics Energy Regulatory Compliance

This Retail Stock Is Down 10% in a Year Despite Record Revenue. A Fund Just Cut Its Stake ↗

May 15, 2026

This global retailer offers apparel and accessories across multiple brands and channels in North America, Europe, and Asia.

Via The Motley Fool

Topics Regulatory Compliance

This Trade School Stock Is Up 135%. Here’s Why a Fund Still Bought 459,000 Shares ↗

May 15, 2026

Lincoln Educational Services delivers hands-on technical and healthcare training across 22 campuses, serving workforce needs nationwide.

Via The Motley Fool

Topics Regulatory Compliance

Callaway Stock Has Soared 150%. Here’s Why One Fund Still Bought 1.1 Million Shares ↗

May 15, 2026

Callaway Golf Company combines branded equipment sales with experiential entertainment through its Topgolf venues and lifestyle offerings.

Via The Motley Fool

Insmed (INSM) Q1 2026 Earnings Transcript ↗

May 07, 2026

Insmed (INSM) Q1 2026 Earnings Transcript

Via The Motley Fool

This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story ↗

March 21, 2026

This biotech firm develops therapies for rare, complement-driven diseases, with a focus on autoimmune and inflammatory conditions.

Via The Motley Fool

Topics Regulatory Compliance

This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch ↗

March 21, 2026

Cogent Biosciences develops targeted therapies for genetically defined diseases, focusing on precision medicine for rare cancers.

Via The Motley Fool

Topics Regulatory Compliance

This Specialized Heart Monitor Maker Just Caught the Eye of a Major Healthcare Fund ↗

March 20, 2026

RTW Investments loads up on iRhythm Holdings with 1.18M Shares Worth $210 million. iRhythm delivers wearable cardiac monitoring and analytics solutions to healthcare providers and at-risk patients.

Via The Motley Fool

Topics Regulatory Compliance

This $91 Million Position Signals Conviction in a Biotech Stock Eyeing FDA Decision This Year ↗

March 20, 2026

This clinical-stage biotech develops therapies for serious immunological diseases, with a focus on late-stage biologic candidates.

Via The Motley Fool

The Small-Cap Renaissance: Why the Russell 2000 is Leading the Charge in 2026

March 09, 2026

As of March 9, 2026, a dramatic regime shift is unfolding on Wall Street. After years of playing second fiddle to the "Magnificent Seven" and AI-driven mega-caps, small-cap stocks have emerged as the...

Via MarketMinute

Topics Artificial Intelligence Economy Supply Chain

Investment Manager Bets Big on PTCT Stock, Adds 41,000 Shares, According to Recent SEC Filing ↗

March 03, 2026

PTC Therapeutics develops therapies for rare diseases, with a portfolio spanning commercial products and investigational candidates.

Via The Motley Fool

Topics Regulatory Compliance

Investment Firm Adds Nearly $4 Milllion Worth of DYN Shares, According to Recent SEC Filing ↗

March 02, 2026

This clinical-stage biotech develops therapies for rare muscle diseases using its proprietary FORCE platform and research-driven approach.

Via The Motley Fool

Topics Regulatory Compliance

Investment Advisor Bets Big on CMPX Stock, Adds 2.5 Million Shares, According to Latest SEC Filing ↗

March 02, 2026

This clinical-stage biotech develops antibody therapeutics targeting cancer, with a pipeline focused on oncology and immunotherapy markets.

Via The Motley Fool

Topics Regulatory Compliance

Investor Buys Up $81 Million in Praxis Stock as Shares Soar Over 300% in One Year ↗

February 23, 2026

Praxis Precision Medicines develops therapies for neurological and psychiatric disorders, aiming to address unmet needs in the CNS market.

Via The Motley Fool

Topics Regulatory Compliance

This Fund Bet Nearly $40 Million on GRAIL Last Quarter. The Stock Just Plunged Over 50% ↗

February 23, 2026

GRAIL develops advanced cancer detection technologies, serving healthcare providers and individuals seeking early diagnostic solutions.

Via The Motley Fool

Topics Regulatory Compliance

Insmed (INSM) Q4 2025 Earnings Call Transcript ↗

February 19, 2026

Insmed (INSM) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Biotech Exit: $26 Million Arcellx Sale Follows Tepid Stock Performance and Kelonia Competition ↗

February 17, 2026

Arcellx develops cell-based immunotherapies targeting cancer, with a lead candidate in early-stage trials for multiple myeloma.

Via The Motley Fool

Topics Regulatory Compliance

Cogent Biosciences Stock Up 346% as Fund Builds $29 Million Stake After November Phase 3 Breakthrough ↗

February 17, 2026

Cogent Biosciences develops precision therapies for genetically defined diseases, with a pipeline targeting rare oncological conditions.

Via The Motley Fool

Topics Regulatory Compliance

Fund Discloses $35 Million Biotech Buy Amid Staggering 830% Terns Stock Surge ↗

February 17, 2026

This clinical-stage biotech develops therapies for NASH and obesity, advancing a diverse pipeline of small-molecule drug candidates.

Via The Motley Fool

Topics Regulatory Compliance

Biotech Stock Up 266%: This New $55 Million Bet Signals Conviction in Praxis Amid Pipeline Progress ↗

February 14, 2026

Praxis Precision Medicines develops therapies for central nervous system disorders, with candidates targeting depression and epilepsy.

Via The Motley Fool

Topics Regulatory Compliance

Apogee Stock Jumps 87% in One Year as This Biotech Fund Lifts Stake to $93 Million ↗

February 14, 2026

This clinical-stage biotech develops monoclonal antibody therapies targeting chronic inflammatory and immunological diseases.

Via The Motley Fool

Topics Regulatory Compliance

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM

January 20, 2026

From Pomerantz LLP

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.